SLC2A1 and cancer: The key innovation lies in the conjugation of d-glucosamine to a widely used chelator, para-isothiocyanatobenzyl-diethylenetriaminepentaacetic acid, to improve selective uptake into cancer cells via GLUT-mediated pathways.